SCHEDULE 13G/A: Anson Funds Management and Affiliates Disclose 0.98% Stake in Universe Pharmaceuticals, Inc.
Beneficial Ownership Disclosure
Anson Funds Management LP and its affiliated entities, including Anson Management GP LLC, Anson Advisors Inc., and key individuals Tony Moore, Amin Nathoo, and Moez Kassam, have disclosed a collective beneficial ownership of 0.98% of Universe Pharmaceuticals, Inc.'s Ordinary Shares.
Summary
- Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo, and Moez Kassam collectively beneficially own 234,374 Ordinary Shares of Universe Pharmaceuticals, Inc.
- This beneficial ownership represents 0.98% of the outstanding Ordinary Shares of Universe Pharmaceuticals, Inc.
- The percentage is calculated based on 23,645,974 Ordinary Shares issued and outstanding as of the Issuer's Annual Report on Form 20-K filed on April 29, 2025, plus 234,374 Ordinary Shares receivable upon exercise of outstanding warrants.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a standard disclosure of an investment firm's passive stake in a publicly traded company within the pharmaceutical sector. It does not provide specific industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The filing indicates a passive ownership stake by a group of investment entities and individuals, which typically does not imply an intent to influence corporate control. This provides transparency regarding significant, albeit non-controlling, shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement. |
| 04/29/2025 | Date of Issuer's Annual Report on Form 20-K filing with the SEC, reporting 23,645,974 Ordinary Shares issued and outstanding. |
| 05/15/2025 | Signature date for the Schedule 13G filing. |
Keywords
Universe Pharmaceuticals, Anson Funds Management, SEC filing, Schedule 13G, beneficial ownership, Ordinary Shares, investment advisor, institutional investor, pharmaceuticals, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.